65,437 trials
Persistent Atrial Fibrillation · Paroxysmal Atrial Fibrillation
Primary: Freedom From Atrial Fibrillation Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Recurrence at 12 Months Post Procedure. — 72; 76 Participants
Human Immunodeficiency Virus
Primary: Steady State Plasma Concentrations of Doravirine After Drug Intake Cessation up to 72 Hours Post-dose. — 18354; 26338 ng*hr/mL
Adult T-Cell Lymphoma (ATL)
Primary: Objective Response Rate — 7 Participants
Other Cancer
Primary: Percentage of Participants Recruited — 20; 20 Participants
Mild Cognitive Impairment · Alzheimer Disease
Primary: Change in Blood Neurofilament Light (NfL) Levels as Measured by Blood Biomarker Assay — 30.09; 44.25 pg/mL — p=>0.05
Chronic Pain
Primary: Percentage of Subjects With 30% or Greater Reduction in Back Pain at 6 Months — 11 Participants
Stress · Carer Stress Syndrome · Dementia
Primary: Change in Global Health - PROMIS (Patient Reported Outcomes Measurement Information System) — 27.23; 27.13; 27.52; 27.23 score on a scale
Atherosclerosis
Primary: The Primary Effectiveness Endpoint-Acute Reduction of Percent Diameter Stenosis — 39.3; 42.8; 39.9 percentage of DS(diameter stenosis)
Pulmonary Disease, Chronic Obstructive
Primary: Sleep Quality Using the PSQI Questionnaire — -0.5; 1 score on a scale
Breast Cancer
Primary: Complication Rate — 15; 20 percentage of participants
Pain, Procedural
Primary: Post Operative Pain — 13; 10 Participants
Healthy
Primary: Postprandial Serum Lipids — 1.01; 0.94; 0.99; 0.97 mmol/L
Aging · Cognitive Ability, General
Primary: Functional Magnetic Resonance Imaging (fMRI) Brain Scan as a Measure of Brain Function — -0.442; -0.203; 0.018; 0.033 units on a scale
Peripheral T-Cell Lymphoma (PTCL)
Primary: Objective Response Rate — 21 Participants
Lymphoma
Primary: Safety of LO-CHOP — 70; 0 percentage of participants